Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University of Colorado, Denver | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to learn about the impact of continuous glucose monitoring (CGM) on families with newly diagnosed children with type 1 diabetes (T1D). The investigators hope to learn about how continuous glucose monitoring affects glycemic variables and diabetes-related distress.
Synopsis of study protocol
This pilot randomized clinical trial compares newly diagnosed T1D youth who are started on CGM (the intervention group) versus those who are not (the control group). The investigators will examine group differences over a 6-month period (Phase 1) on two sets of outcomes: psychosocial variables and glycemic variables. After the initial comparison of intervention to control across the first six months after diagnosis, the investigators will conduct a longitudinal follow-up (Phase 2) of glycemic and psychosocial variables for an additional 18 months. The CGM system used in this study is the Dexcom G5 System with the Share function (FDA Approved). An IDE was obtained to use this system in a non-adjunctive manner. Participants will complete Phase 1 in six months. Phase 2 includes 3 more assessments conducted every six months until participants are two years post-diagnosis.
Study Procedures
Participants will be recruited at two centers: Stanford University and the Barbara Davis Center for Diabetes, University of Colorado. Participants will be enrolled while inpatient or within 1 month of diagnosis. Once identified, study staff will approach potential participants to explain the study, determine eligibility, and obtain informed consent. Once enrolled in the study, participants will be randomized. Participants will be randomized at a 2:1 ratio, intervention to control. The investigators will also stratify by age group to ensure equal representation of ages across groups. The age groups (in years) are 2-6, 7-11, and 12-17. To ensure safety in the youngest group, recruitment of participants in the age 2-6 years group will not begin until the investigators have at least 2 weeks of non-adjunctive CGM use data in at least 3 participants aged 7-17 years. Data will be reviewed by the DSMB on these 3 participants and if deemed safe by the DSMB, the investigators will start enrolling participants in the youngest age group.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| CGM at diagnosis of T1D | Experimental | Participants start non-adjunctive use of CGM at diagnosis of T1D and continue for 6 months. |
|
| Usual Care | No Intervention | Participants receive usual care for T1D for 6 months post diagnosis. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| CGM at diagnosis of T1D | Device | Initiation of non-adjunctive CGM use at diagnosis of T1D |
|
| Measure | Description | Time Frame |
|---|---|---|
| Time Spent in Blood Glucose Range (70-180mg/dL) | Increasingly it is recognized that the percent time spent in a target blood glucose range, which is set by the American Diabetes Association, is an important outcome. This measure will be used as a primary outcome and derived from objective data downloads. It is calculated using the values for 14 days around the assessment time point. | Collected entire period for 6 months post-baseline; primary endpoint is 14 day period around that 6-month time point |
| Glucose Monitoring Satisfaction Survey (GMSS) - Parent | The GMSS is a validated survey created to measure the level of satisfaction a person with diabetes - type 1 or type 2 - experiences in response to monitoring glucose values. It was validated in people using CGM. Scores range 0 to 5 with higher scores indicating greater satisfaction. | Baseline, 24 months |
| Time Spent in Hypoglycemia (< 70 mg/dL) | Time spent in hypoglycemia is calculated using the values for 14 days around the assessment time point. | Collected entire period for 6 months post-baseline; primary endpoint is 14 day period around that 6-month time point |
| Measure | Description | Time Frame |
|---|---|---|
| Pediatric Quality of Life Inventory | This is a measure of health-related quality of life. It is used to understand the broader impact on quality of life which includes social, psychological, and health aspects of daily living. Scores range from 0 to 100. Higher scores indicate greater quality of life. | Baseline, 24 months |
Not provided
Inclusion Criteria:
To be eligible for the study, a child must meet the following criteria:
To be eligible for the study, a parent must meet the following criteria:
Exclusion Criteria:
The presence of any of the following is an exclusion for the study:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Korey K Hood, PhD | Stanford University | Principal Investigator |
| Bruce Buckingham, MD | Stanford University | Principal Investigator |
| Paul Wadwa, MD | University of Colorado, Denver | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Stanford University | Stanford | California | 94305 | United States | ||
| University of Colorado |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Both youth and parent were enrolled; parents were enrolled for assessments of surveys only, youth under 11 years of age did not complete surveys.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | CGM at Diagnosis of T1D | Participants start non-adjunctive use of continuous glucose monitoring (CGM) at diagnosis of type 1 diabetes (T1D) and continue for 6 months. CGM at diagnosis of T1D: Initiation of non-adjunctive CGM use at diagnosis of T1D Both groups followed through for up to 24 months |
| FG001 | Usual Care | Participants receive usual care for T1D for 6 months post diagnosis. Both groups followed through for up to 24 months |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Only youth were assessed for baseline characteristics.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | CGM at Diagnosis of T1D | Participants start non-adjunctive use of CGM at diagnosis of T1D and continue for 6 months. CGM at diagnosis of T1D: Initiation of non-adjunctive CGM use at diagnosis of T1D Both groups followed through for up to 24 months |
| BG001 | Usual Care |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Time Spent in Blood Glucose Range (70-180mg/dL) | Increasingly it is recognized that the percent time spent in a target blood glucose range, which is set by the American Diabetes Association, is an important outcome. This measure will be used as a primary outcome and derived from objective data downloads. It is calculated using the values for 14 days around the assessment time point. | This outcome was assessed in youths only. | Posted | Mean | Standard Deviation | percentage of time | Collected entire period for 6 months post-baseline; primary endpoint is 14 day period around that 6-month time point |
|
24 months
Adverse events were assessed in youths only.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | CGM at Diagnosis of T1D | Participants start non-adjunctive use of CGM at diagnosis of T1D and continue for 6 months. CGM at diagnosis of T1D: Initiation of non-adjunctive CGM use at diagnosis of T1D |
Not provided
Not provided
Primary and secondary survey outcome data is limited to participants with complete records.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Korey Hood | Stanford University | 6504976899 | kkhood@stanford.edu |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Dec 22, 2015 | Apr 30, 2021 | Prot_SAP_000.pdf |
| ICF | No | No | Yes | Informed Consent Form | Jan 22, 2019 | Apr 30, 2021 | ICF_001.pdf |
Not provided
| ID | Term |
|---|---|
| D003922 | Diabetes Mellitus, Type 1 |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Problem Areas in Diabetes Score |
Participants in the study report on daily problems with diabetes via this measure. Respondents indicate the degree to which each of the items is currently a problem for them. Score range: 0 to 4, higher scores correspond to more serious problems. |
| Baseline, 24 months |
| Diabetes Distress Scale | This measure is widely used to capture the psychological distress experienced in relation to diabetes. Parent scale score range: 0-4. Youth scale score range: 1-6. Higher scores indicate greater diabetes-related distress. | Baseline, 24 months |
| Patient Health Questionnaire 9 | This is a widely used measure that captures depressive symptoms, and was used to assess health symptoms in parents. Score range: 0-24. Higher scores indicate greater severity of symptoms. | Baseline, 24 months |
| State-Trait Anxiety Inventory | This is a widely used measure of anxiety symptoms, and was used to assess anxiety symptoms in parents. Score range for both state-anxiety is: 20-80. Higher scores indicate greater anxiety. | Baseline, 24 months |
| Pittsburgh Sleep Quality Index | This questionnaire measures the degree to which sleep is disrupted and the quality of sleep experienced by participants, and was used to assess sleep quality in parents. Score range is: 0-21. Higher scores indicate lower sleep quality. | Baseline, 24 months |
| Hypoglycemic Fear Survey | People with diabetes worry about hypoglycemia, and was used to assess parent's worry about their child. This measure captures those worries. Score range: 0-72. Higher scores indicate greater fear and worry of hypoglycemia. | Baseline, 24 months |
| Hypoglycemic Confidence Questionnaire | Hypoglycemia needs to be managed in various daily situations. This questionnaire captures confidence of the participants in those various situations, and was used to assess parent's confidence. Score range: 8-32. Higher scores indicate greater confidence to manage hypoglycemia. | Baseline, 24 months |
| General and Diabetes-specific Technology Use | This measure has questions on attitudes and use of various general technologies (e.g., smartphone) and diabetes devices. Score range: 5-25. Higher scores indicate more positive attitudes about technology. | Baseline, 24 months |
| Center for Epidemiologic Studies Depression Measure | This is a widely used measure of depression, and was used to assess depression symptoms in youths. Score range: 0-60. Higher scores indicate greater symptoms. | Baseline, 24 months |
| Child Health Utility 9D | Widely used measure of quality of life that is used to generate quality-adjusted life years, and was used to assess health symptoms in youth. Each score scale is 0 to 4, with scores of 3 or 4 denoting more severe problems. The count of participants responding 3 or higher for each parameter are presented. | Baseline, 24 months |
| Hemoglobin A1c | The hemoglobin A1c value is a biologic measure of the glycemia that is the gold standard measure of "control" of diabetes. Collected through a blood sample. | Baseline, 24 months |
| C-peptide | This is a biologic measure of endogenous production and is collected through a blood sample. | Baseline, 24 months |
| Aurora |
| Colorado |
| 80045 |
| United States |
Participants receive usual care for T1D for 6 months post diagnosis. Both groups followed through for up to 24 months |
| BG002 | Total | Total of all reporting groups |
| Participants |
|
| Age, Continuous | Mean | Standard Deviation | years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Count of Participants | Participants |
|
| OG001 | Usual Care | Participants receive usual care for T1D for 6 months post diagnosis. Both groups followed through for up to 24 months |
|
|
|
| Primary | Glucose Monitoring Satisfaction Survey (GMSS) - Parent | The GMSS is a validated survey created to measure the level of satisfaction a person with diabetes - type 1 or type 2 - experiences in response to monitoring glucose values. It was validated in people using CGM. Scores range 0 to 5 with higher scores indicating greater satisfaction. | Participants with complete data (by youth and parent) are included in the analysis. | Posted | Mean | Standard Deviation | score on a scale | Baseline, 24 months |
|
|
|
|
| Primary | Time Spent in Hypoglycemia (< 70 mg/dL) | Time spent in hypoglycemia is calculated using the values for 14 days around the assessment time point. | This outcome was assessed in youths only. | Posted | Mean | Standard Deviation | percentage of time | Collected entire period for 6 months post-baseline; primary endpoint is 14 day period around that 6-month time point |
|
|
|
|
| Secondary | Pediatric Quality of Life Inventory | This is a measure of health-related quality of life. It is used to understand the broader impact on quality of life which includes social, psychological, and health aspects of daily living. Scores range from 0 to 100. Higher scores indicate greater quality of life. | Participants with complete data (by youth and parent) are included in the analysis. | Posted | Mean | Standard Deviation | score on a scale | Baseline, 24 months |
|
|
|
| Secondary | Problem Areas in Diabetes Score | Participants in the study report on daily problems with diabetes via this measure. Respondents indicate the degree to which each of the items is currently a problem for them. Score range: 0 to 4, higher scores correspond to more serious problems. | Participants with complete data (by youth and parent) are included in the analysis. | Posted | Mean | Standard Deviation | score on a scale | Baseline, 24 months |
|
|
|
| Secondary | Diabetes Distress Scale | This measure is widely used to capture the psychological distress experienced in relation to diabetes. Parent scale score range: 0-4. Youth scale score range: 1-6. Higher scores indicate greater diabetes-related distress. | Participants with complete data (by youth and parent) are included in the analysis. | Posted | Mean | Standard Deviation | score on a scale | Baseline, 24 months |
|
|
|
| Secondary | Patient Health Questionnaire 9 | This is a widely used measure that captures depressive symptoms, and was used to assess health symptoms in parents. Score range: 0-24. Higher scores indicate greater severity of symptoms. | Parent participants with complete data are included in the analysis. Youth did not complete this measure. | Posted | Mean | Standard Deviation | score on a scale | Baseline, 24 months |
|
|
|
| Secondary | State-Trait Anxiety Inventory | This is a widely used measure of anxiety symptoms, and was used to assess anxiety symptoms in parents. Score range for both state-anxiety is: 20-80. Higher scores indicate greater anxiety. | Parent participants with complete data are included in the analysis. Youth did not complete this measure. | Posted | Mean | Standard Deviation | score on a scale | Baseline, 24 months |
|
|
|
| Secondary | Pittsburgh Sleep Quality Index | This questionnaire measures the degree to which sleep is disrupted and the quality of sleep experienced by participants, and was used to assess sleep quality in parents. Score range is: 0-21. Higher scores indicate lower sleep quality. | Parent participants with complete data are included in the analysis. Youth did not complete this measure. | Posted | Mean | Standard Deviation | score on a scale | Baseline, 24 months |
|
|
|
| Secondary | Hypoglycemic Fear Survey | People with diabetes worry about hypoglycemia, and was used to assess parent's worry about their child. This measure captures those worries. Score range: 0-72. Higher scores indicate greater fear and worry of hypoglycemia. | Parent participants with complete data are included in the analysis. Youth did not complete this measure. | Posted | Mean | Standard Deviation | score on a scale | Baseline, 24 months |
|
|
|
| Secondary | Hypoglycemic Confidence Questionnaire | Hypoglycemia needs to be managed in various daily situations. This questionnaire captures confidence of the participants in those various situations, and was used to assess parent's confidence. Score range: 8-32. Higher scores indicate greater confidence to manage hypoglycemia. | Participants with complete data (by youth and parent) are included in the analysis. | Posted | Mean | Standard Deviation | score on a scale | Baseline, 24 months |
|
|
|
| Secondary | General and Diabetes-specific Technology Use | This measure has questions on attitudes and use of various general technologies (e.g., smartphone) and diabetes devices. Score range: 5-25. Higher scores indicate more positive attitudes about technology. | Participants with complete data (by youth and parent) are included in the analysis. | Posted | Mean | Standard Deviation | score on a scale | Baseline, 24 months |
|
|
|
| Secondary | Center for Epidemiologic Studies Depression Measure | This is a widely used measure of depression, and was used to assess depression symptoms in youths. Score range: 0-60. Higher scores indicate greater symptoms. | Youth participants with complete data are included in the analysis. Parents did not complete this measure. | Posted | Mean | Standard Deviation | score on a scale | Baseline, 24 months |
|
|
|
| Secondary | Child Health Utility 9D | Widely used measure of quality of life that is used to generate quality-adjusted life years, and was used to assess health symptoms in youth. Each score scale is 0 to 4, with scores of 3 or 4 denoting more severe problems. The count of participants responding 3 or higher for each parameter are presented. | Youth participants with complete data are included in the analysis. Parents did not complete this measure. | Posted | Count of Participants | Participants | Baseline, 24 months |
|
|
|
| Secondary | Hemoglobin A1c | The hemoglobin A1c value is a biologic measure of the glycemia that is the gold standard measure of "control" of diabetes. Collected through a blood sample. | Youth participants with complete data are included in the analysis. Parents are not included in this measure. | Posted | Mean | Standard Deviation | mg/dL | Baseline, 24 months |
|
|
|
| Secondary | C-peptide | This is a biologic measure of endogenous production and is collected through a blood sample. | Youth participants with complete data are included in the analysis. Parent data was not collected. | Posted | Mean | Standard Deviation | ng/mL | Baseline, 24 months |
|
|
|
| 0 |
| 42 |
| 0 |
| 42 |
| 0 |
| 42 |
| EG001 | Usual Care | Participants receive usual care for T1D for 6 months post diagnosis. | 0 | 18 | 0 | 18 | 0 | 18 |
Not provided
Not provided
| D004700 | Endocrine System Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
| Youth - 24 months |
|
|
| Parent - baseline |
|
|
| Parent - 24 months |
|
|
| Youth - 24 months |
|
|
| Parent - baseline |
|
|
| Parent - 24 months |
|
|
| Youth - 24 months |
|
|
| Parent - baseline |
|
|
| Parent - 24 months |
|
|
| Youth - 24 months |
|
|
| Parent - baseline |
|
|
| Parent - 24 months |
|
|
| Youth - 24 months |
|
|
| Parent - baseline |
|
|
| Parent - 24 months |
|
|
| Youth - 24 months |
|
|
| Parent - baseline |
|
|
| Parent - 24 months |
|
|
| Youth - baseline sad |
|
| Youth - 24 months sad |
|
| Youth - baseline pain |
|
| Youth - 24 months pain |
|
| Youth - baseline tired |
|
| Youth - 24 months tired |
|
| Youth - baseline annoyed |
|
| Youth - 24 months annoyed |
|
| Youth - baseline schoolwork |
|
| Youth - 24 months schoolwork |
|
| Youth - baseline sleep |
|
| Youth - 24 months sleep |
|
| Youth - baseline routine |
|
| Youth - 24 months routine |
|
| Youth - baseline activities |
|
| Youth - 24 months activities |
|